

Review of: "Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports"

Atakan Yucel

Potential competing interests: No potential competing interests to declare.

This article presents a review of the effectiveness and safety of antipsychotic medications such as Risperidone and Paliperidone in the treatment of patients with schizophrenia or bipolar disorder. The authors address the shortcomings of existing evidence relying solely on aggregate data by utilizing individual participant data (IPD), clinical study reports (CSR), and public sources (journal publications and trial registries).

Positive Critiques: The research is conducted with comprehensive literature review and data analysis methods. The use of IPD and CSR enhances the depth of analysis. The study integrates data from different sources, providing access to a broader dataset. The finding that Risperidone and Paliperidone have a small beneficial effect on reducing PANSS scores is significant and could be useful in clinical practice. The observation that CSRs contain more data on adverse events not found in journal publications or trial registries emphasizes the importance of evaluating drug safety more comprehensively.

Negative Critiques: The study only uses data up to specific dates, potentially excluding newer data that could enhance the relevance of the findings. Concerns about serious side effects of Risperidone and Paliperidone, especially regarding hormonal imbalances, play a significant role in treatment choice. It's unclear if the study adequately addresses these side effects. The study provides limited information on gynecomastia, one of the side effects of these antipsychotics. Further investigation of such side effects is crucial^{[1][2][3]}.

In conclusion, this article demonstrates that Risperidone and Paliperidone have a limited but positive effect on reducing PANSS scores. However, the study has some limitations, including data gaps and incomplete consideration of side effects. Considering these critiques, there is a need for more comprehensive studies on the efficacy and safety of these drugs.

References

- ¹ ^ Atakan Yucel, Nermin Yucel, Halil Ozcan, Murat Saritemur. (2015). *Dose-Dependent Paliperidone Associated With Angioedema*. doi:10.1097/jcp.0000000000000368.
- ² ^ A Yucel, N Yucel, H Ozcan, MF Ustundag, et al. (2016). *Recurrent Priapism Related with Low Single Dose*

Olanzapine. *West Indian Med J*. doi:10.7727/wimj.2016.030.

3. [^] Fatih Ozkaya, Department of Urology, Faculty of Medicine, Ataturk University, Erzurum, Turkey, Tevfik Ziypak, Senol Adanur, et al. (2019). The Occurrence of Priapism as a Result of the Use of a Single Dose of Quetiapine *Eurasian J Med*, vol. 44 (2), 122-123. doi:10.5152/eajm.2012.27.